Normal Human Prostate Cell Line Research Articles

Psoralea corylifolia L. extract ameliorates benign prostatic hyperplasia by regulating prostate cell proliferation and apoptosis

Ethnopharmacological relevancePsoralea corylifolia L. seed (PCL), commonly known as “Poguzhi” or “BuguZhi”, has been widely used to treat kidney yang deficiency in traditional Chinese medicine (TCM) where tonifying the yang deficiency is a representative understanding for treatment of hormonal deficiency disorders such as enuresis, oliguria, and prostatic diseases. Although PCL has been commonly used to treat problems of the urinary system, its efficacy against benign prostatic hyperplasia (BPH) has not yet been reported. Aim of the studyIn the present study, we aimed to assess the in vitro and in vivo efficacy of PCL against BPH, a condition which negatively impacts quality of life in men. Materials and methodsNormal human prostate cell lines, RWPE-1 and WPMY-1 cells, were stimulated with 10 nM dihydrotestosterone (DHT) to establish an in vitro BPH model. Subsequently, cells were treated with 100 or 200 μg/ml PCL, which inhibited cell proliferation without cytotoxicity, to evaluate the anti-BPH effect of PCL. Eight-week-old male Wistar rats were castrated, except for those in the control group (Con), and BPH was induced by subcutaneous injection of 10 mg/kg testosterone propionate (TP). Concurrent with daily TP injections, 5 mg/kg of finasteride (Fina) and 50 or 100 mg/kg PCL were orally administrated daily for four weeks, excluding the weekends. ResultsIn DHT-stimulated RWPE-1 and WPMY-1 cells, expression of androgen receptor (AR) androgen signaling-related markers such as 5α-reductase 2 (5AR2), AR, and prostate-specific antigen (PSA) was upregulated, whereas 100 or 200 μg/ml of PCL treatment downregulated these markers. Furthermore, PCL significantly reduced the mRNA expression of anti-apoptotic genes and increased the mRNA expression of pro-apoptotic gene. In vivo, administration of PCL reduced prostate size and weight in TP-induced BPH rats. Moreover, histological alterations in epithelium thickness were significantly restored by the administration of PCL. Immunohistochemical analysis revealed increased expression of AR and proliferating cell nuclear antigen (PCNA) in TP-induced BPH prostates; these changes were suppressed by administration of 50 or 100 mg/kg PCL. ConclusionsWe demonstrated the effect of PCL against BPH, mediated by the regulation of prostate cell proliferation and apoptosis, in DHT-stimulated normal human prostate cell lines and TP-induced BPH rats. These findings suggest that PCL could be a potential therapeutic agent against BPH.

A basal-enriched microRNA is required for prostate tumorigenesis in a Pten knockout mouse model.

MicroRNAs (miRNAs) play important roles in prostate cancer development. However, it remains unclear how individual miRNAs contribute to the initiation and progression of prostate cancer. Here we show that a basal layer-enriched miRNA is required for prostate tumorigenesis. We identify miR-205 as the most highly expressed miRNA and enriched in the basal cells of the prostate. Although miR-205 is not required for normal prostate development and homeostasis, genetic deletion of miR-205 in a Pten null tumor model significantly compromises tumor progression and does not promote metastasis. In Pten null basal cells, loss of miR-205 attenuates pAkt levels and promotes cellular senescence. Furthermore, although overexpression of miR-205 in prostate cancer cells with luminal phenotypes inhibits cell growth in both human and mouse, miR-205 has a minimal effect on the growth of a normal human prostate cell line. Taken together, we have provided genetic evidence for a requirement of miR-205 in the progression of Pten null-induced prostate cancer.

Bioassay-guided isolation and structure elucidation of cytotoxic stilbenes and flavonols from the leaves of Macaranga barteri

Bioassay-guided fractionation of the leaves of Macaranga barteri collected from Nigeria led to the isolation of three previously undescribed cytotoxic stilbenes, macabartebenes A–C (1–3), together with six known compounds including prenylated stilbenes: vedelianin (4), schweinfurthin G (5), and mappain (7), prenylated flavonols: 8-prenylkaempferol (6), and broussoflavonol F (8), and the geranylated flavonol, isomacarangin (9). The cytotoxicity of the compounds was evaluated against four human cancer cell lines, with vinblastine as the positive control and DMSO vehicle as the negative control. Vedelianin (IC50 = 0.32–0.54 μM) displayed the greatest antiproliferative activity across the panel of cancer cell lines amongst the compounds, while macabartebene A (IC50 = 0.60–0.79 μM) was the most potent of the previously unreported compounds. The compounds displayed varying selectivity towards the cancer cell lines compared to the normal human prostate cell line. The findings of this study revealed that M. barteri leaves contain several cytotoxic compounds.

Resveratrol derivatives from Commiphora africana (A. Rich.) Endl. display cytotoxicity and selectivity against several human cancer cell lines.

Commiphora africana (A. Rich.) Endl. (Burseraceae) is a medicinal plant widely used in Nigerian ethnomedicine. The in vitro cytotoxicity of the stem bark extract of C.africana and isolated cytotoxic compounds was investigated. Three resveratrol derivatives: (E)-resveratrol 3-O-rutinoside (1), 5-methoxy-(E)-resveratrol 3-O-rutinoside (2), and pinostilbene (3), together with 3-hydroxy-5-methoxybenzoic acid (4) were isolated from the methanol fraction of C.africana. Their structures were determined by extensive analysis of their HREIMS and NMR spectra. The cytotoxicity of the isolated compounds against four human carcinoma cells was determined using the MTT assay. Compound 1 displayed the highest antiproliferative effect on the cell lines, with IC50 values of 16.80, 21.74, 17.89, and 17.44μM, against MCF7, A549, PC3, and HepG2 human cancer cell lines, respectively. In addition, compounds 1-3 showed low toxicity against normal human prostate cell line, with selectivity indices greater than five across the carcinoma cells, indicating that the compounds possess potential in the development of low-toxicity chemotherapeutic agents. These results support the traditional use of this plant in the treatment of cancer.

Abstract 4436: Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) is upregulated modulates prostate cancer growth and proliferation

Abstract Introduction: cap-dependent translation is necessary due to high protein requirement in cancer cells. An interaction between EIF4E and EIF4G is crucial for the formation of the EIF4F complex and initiation of cap-dependent translation. In the current study, we analyzed Human prostate cancer tissue microarray (TMA) and mRNA expression data in clinical datasets, and prostate tumor tissue from TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) model. We also assessed the functional role of EIF4G1 in commonly used PCa cell lines. Methods: Human prostate cancer tissue microarray was used to analyze the EIF4G1 level in patient samples. mRNA expression data for EIF4G1 was analyzed from TCGA and Trento/Cornell/Broad clinical data sets. PCa cells viz. LNCaP, C4-2b, 22Rv1, DU145, PC3 and normal human prostate cell line RWPE-1 were used. For an in-vivo model of PCa, we used TRAMP and wild-type mouse. Loss of function studies was performed by using siRNA/shRNA. Real-time PCR and Western Blot analysis were used to quantitate the relative mRNA and protein levels respectively. Analysis of polysome was performed by sucrose density gradient fractionation. Polysome-to-Monosome (P/M) ratios were determined for global translation activity. Cell cycle, cell proliferation, cell migration and Clonogenic activity were measured by standard methods. Results: Results from TMA analysis showed that protein levels of EIF4G1 are high in PCa as compared to normal prostate tissue, and there is a graded increase in EIF4G1 as the disease progresses. Results of our analysis of EIF4G1 expression in TCGA database revealed that increased expression of EIF4G1 positively correlated with higher tumor grade and stages (Gleason Score). Available data from Trento/Cornell/Broad clinical dataset revealed that 43% of castration-resistant prostate cancer (CRPC) patients have EIF4G1 mRNA up-regulation. PCa cells express a significantly higher level of EIF4G1 as compared to normal prostate cells. Similarly, prostate tumor tissue from TRAMP tissue showed higher EIF4G1 expression as compared to normal wild-type prostate tissue. Silencing of EIF4G1 causes G0/G1 cell cycle delay and decreases Cyclin D1 and p-Rb levels. There is a shift in polysome (P) to monosome (M) ratio with the siEIF4G1 knockdown in LNCaP and C4-2b. Loss of function studied by knockdown of EIF4G1 showed impaired Clonogenic activity as well as cell proliferation. Real-time PCR data suggests that EIF4G1 knockdown in LNCaP & C4-2b decreases the level of EMT markers such as N-Cadherin, Vimentin & Zeb1 and limits the cell migration in C4-2b cells. Conclusions: Taken all together, our data indicate that EIF4G1 may function as an oncoprotein and is a novel target for intervention in PCa and CRPC. Citation Format: Praveen K. Jaiswal, Sweaty Koul, Prakash Srinivasan Timiri Shanmugam, Hari K. Koul. Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) is upregulated modulates prostate cancer growth and proliferation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4436.

One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.

A facile one-pot method for the synthesis of novel podophyllotoxin-thiourea congeners has been developed by using NH2SO3H/NaI system. Interestingly, 4β-azido podophyllotoxin reduction with concomitant aryl isothiocyanates coupling under mild reaction conditions has been achieved. These compounds have been investigated for their in vitro cytotoxicity against A549, MDA MB-231, DU-145, LNCaP, and HGC-27 cancer cell lines. Some of the representative compounds have selectively exhibited cytotoxicity on DU-145 (human prostate cancer) cells and the most potent compound was 4a (IC50 of 0.50 ± 0.03 μM) with optimal safety therapeutic window (81.7 fold) on normal human prostate cell line (RWPE-1, IC50 of 40.85 ± 0.78). The flow-cytometric analysis of the compound 4a in prostate cancer cells indicated a strong G2/M-phase arrest and significant topoisomerase II inhibition activity. Furthermore, these compounds induce apoptosis as observed by Acridine Orange and Ethidium Bromide (AO/EB) staining and Annexin V binding assay. Molecular docking results of the title compounds with topoisomerase-IIα were presented as theoretical support for the experimental data.

Abstract 3194: Platycodin D induces growth arrest and cell cycle arrest by activating MDM2 and interacting with FOXO3a in prostate cancer

Abstract Purpose: The present study was designed to evaluate the anti-tumor activity and possible mechanism of action of Platycodin D (PD), a major saponin derived from Platycodin grandiflorum, in human prostate cancer. Experimental Design: Human prostate cancer cells with different p53 status (p53 wildtype LNCaP cells, p53 null PC3 cells and p53 mutant DU145 cells), and the normal human prostate cell line, RWPE-1, were exposed to various concentrations of PD to compare its cytotoxicity in vitro (via the MTT assay). Detailed invitro and invivo studies on the anti-tumor effects of PD were then performed. Results: PD exerted cytotoxicity against all three prostate cancer cell lines, with half-maximal inhibitory concentrations in the range of 11.16 to 26.13μmol/L. The PC3 cells were the most sensitive to PD, whereas RWPE-1 cells were not sensitive to PD.A further study in these cell lines showed that PD could potently affect the cell proliferation (indicated by the bromodeoxyuridine assay), induce cell apoptosis (by Annexin V-FITC flow cytometry) and cause cell cycle arrest (PI staining). After being treated with PD for 48 hours,the DU145 and LNCaP cells were arrested in the G0 /G1 phase, and the PC3 cells were arrested in the G2/M phase. A Western blot analysis indicated that PD decreased the expression of MDM2 and increased the expression levels of FOXO3a, p21 and p27 in the three cell lines. In PC3 cells, PD exposure decreased the levels of cell cycle-related proteins, including E2F1, cdk2, cdk4, cdk6, cyclin D1 and cdc2. PD exposure increased apoptosis-related proteins, Bax, caspase9 and caspase3, and downregulated Bcl-2, PARP, and caspase8. Real-time PCR indicated that the same changes had occurred at the transcriptional level for all of these targets. Moreover, PD dose-dependently inhibited the growth of PC3 xenograft tumors in BALB/c nude mice. A Western blot analysis of the xenograft tumors indicated that similar changes in protein expression also occurred in vivo. Conclusion: PD exhibits significant activity against prostate cancer cells in a p53-independent manner. MDM2 and the FOXO3a transcription factor appear to be involved in the mechanism of action of PD, which provides a basis for future development of this agent for human prostate cancer therapy. Citation Format: Hongxia Xu, Rui Zhou, Zongliang Lu, Kai Liu. Platycodin D induces growth arrest and cell cycle arrest by activating MDM2 and interacting with FOXO3a in prostate cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3194. doi:10.1158/1538-7445.AM2014-3194

Docosahexaenoic acid selectively induces human prostate cancer cell sensitivity to oxidative stress through modulation of NF‐κB

Oxidative burden is strongly implicated in the pathogenesis of age-related diseases, including prostate cancer tumor formation. As omega-3 fatty acids possess known antioxidant properties, we investigated the effects of docosahexaenoic acid (DHA-22:6n-3), one component of fish oil, in modulating the effects of oxidative DNA damage in LNCaP and PacMetUT1 human prostate adenocarcinoma cells and in a normal human prostate cell line, PrEC. Cell survival was determined by an inhibition of colony formation assay. DNA double-strand breaks, NF-κB subcellular localization and relative survivin expression levels were determined by immunofluorescence and survivin expression levels confirmed by immunoblot assay. Measurement of NF-κB transcriptional activity was investigated by dual luciferase assay. LNCaP and PacMetUT1 cells pretreated with DHA and pulsed with 32 µM H(2) O(2) exhibit decreased survival compared to PrEC. γ-H2AX foci, indicating DNA double-strand breaks, were associated with translocation of NF-κB into the nucleus, whereas exposure to DHA prior to H(2) O(2) treatment prevented NF-κB translocation. Further, DHA attenuated H(2) O(2) -induced NF-κB transcriptional activity and diminished expression of the downstream target, survivin. NF-κB is heavily implicated in promoting prosurvival signaling and may be critical for resistance to the chronic oxidative stress observed in the pathogenesis of prostate cancer. Our studies indicate that exposure of cells to physiologically achievable levels of DHA prior to treatment with H(2) O(2) results in decreased cancer cell survival which is associated with nuclear exclusion of NF-κB. We therefore propose that DHA selectively sensitizes prostate cancer cells to growth arrest through attenuation of the NF-κB survival pathway.

Expression of aquaporin 3 in the human prostate

Aquaporins (AQPs) function as selective pores allowing water, glycerol and other small solutes to pass through the cell membrane. The present study investigated the expression and localization of AQP3 in the human prostate. Three human prostate cancer cell lines (DU-145, LNCaP and PC-3) and one normal human prostate cell line (PNT1A) were used in this study. Clinical materials from patients with prostate cancer were also used. AQP3 mRNA and protein expression were examined using reverse transcription-polymerase chain reaction and immunohistochemical methods. Aquaporin 3 mRNA was expressed in normal and cancerous prostate cells. Moreover, the expression of AQP3 mRNA was seen in both normal and cancerous epithelia of human prostate tissues, but not in the mesenchyme. In the normal epithelia of the prostate, localization was limited to cell membranes, particularly the basolateral membranes. However, the expression of AQP3 protein in the cancer epithelia was not observed on the cell membranes. The results suggest that water-channel protein may be involved in the preservation of cellular character in the human prostate and prostate cancer is associated with an alteration of water-transporting mechanisms. Changes in the localization of AQP3 in cancer cells may result from tumorigenesis.

In-vitro effects of polyphenols from cocoa and β-sitosterol on the growth of human prostate cancer and normal cells

Cocoa contains many different types of physiologically active components. It was shown that cocoa beans are rich in specific antioxidants such as flavonoids, catechins, epicatechins and proanthocyanidins. Additionally, beta-sitosterol, the most common phytosterol, may play a protective role in the development of cancer. The aim of this in-vitro study was to evaluate the inhibitory effect of different cocoa polyphenols extracts, alone or combined with beta-sitosterol, on two human prostate cancer cell lines (nonmetastatic 22Rv1 cells and metastatic DU145 cells) and a normal human prostate cell line (RWEP-1). A synergy between beta-sitosterol and cocoa polyphenols extract was also researched. Cells were treated independently with five products from 1 to 72 h: (1/) synthetic beta-sitosterol, (2/) a cocoa polyphenols extract supplemented with beta-sitosterol, (3/) three different cocoa polyphenols extracts naturally containing beta-sitosterol. In the experiment, beta-sitosterol was tested from 10(-6) to 10(-3)%; cocoa polyphenols extract supplementation was with 0.72% beta-sitosterol; finally cocoa polyphenols extracts were added to the cells at very low concentrations ranging from 0.001 to 0.2%. The growth and viability of cells were measured using colorimetric assay at 1, 3, 6, 24, 48 and 72 h of treatment. IC50 and IC100 corresponding to the concentration leading to a decrease of 50% and 100% of cell growth were determined. At the highest tested concentration, cocoa polyphenols extracts induced a complete inhibition of growth of metastatic and nonmetastatic cancer cell lines. In addition, cocoa polyphenols extracts were more active against local cancer cells than against metastatic cells. Moreover, at the highest tested concentration, cocoa polyphenols extracts are not effective on a normal prostate cell lines. Beta-sitosterol induced low growth inhibition of both cancer cell line. Cocoa polyphenols extracts, however, were significantly more active and showed a strong and fast inhibition of cell growth than beta-sitosterol alone. No synergy or addition was observed when beta-sitosterol was tested together with the cocoa polyphenols extract. Our results show that cocoa polyphenols extracts have an antiproliferative effect on prostate cancer cell growth but not on normal cells, at the highest tested concentration.

Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion.

The regulation of cell adhesion and motility in human prostate is not well understood. We have previously shown that the endoglin gene is differently expressed during changes in prostate cell adhesion. Endoglin is a transmembrane transforming growth factor beta binding protein typically expressed by endothelial cells. In this report we demonstrate that endoglin over expression increases prostate cell attachment, while decreasing migration and invasion. Engineered decreases in endoglin expression have opposite effects. While endoglin exerted only relatively small effects upon cell adhesion, large effects upon cell migration and invasion were observed. Endoglin was shown to localize to focal adhesion plaques, consistent with its role in regulating cell adhesion and motility. Loss of endoglin expression in cancer, as compared to normal prostate, was seen in human prostate cell lines. Suppression of endoglin expression in a panel of normal human prostate cell lines led to cell detachment. Endoglin is identified as a regulator of cell adhesion, motility and invasion in human prostate. Loss of endoglin expression appears to be associated with prostate cancer progression, at least in vitro.